Flag of the European Union EU Clinical Trials Register Help

Clinical trials for BVD

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: BVD. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-020072-33 Sponsor Protocol Number: BVD-CLEM 01-10 Start Date*: 2011-02-10
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma
    Medical condition: Relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051381 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004358-14 Sponsor Protocol Number: BVDStudy Start Date*: 2017-01-18
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA
    Full Title: Bromfenac 0.09% versus dexamethasone 0.1% ophthalmic solutions to reduce inflammation after cataract surgery: the BVD Study.
    Medical condition: Postoperative ocular inflammation after cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015943 Eye inflammation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012359-91 Sponsor Protocol Number: IFM 2009-01 Start Date*: 2009-10-21
    Sponsor Name:Intergroupe Francophone du Myélome
    Full Title: Multicenter Phase II Study of Bendamustine, Velcade (Bortezomib) and Dexamethasone (BVD) in the treatment of elderly patients (> or =65 years) with multiple myeloma in 1st relapse or refractory to ...
    Medical condition: Patient with Multiple Myeloma (MM) in 1st relapse or refractory to 1st line therapy, having received 1st line therapy with conventional chemotherapy without stem cell transplantation (patients 65 y...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000769-19 Sponsor Protocol Number: CBEZ235Z2401 Start Date*: 2012-10-25
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors
    Medical condition: Adult patient in advanced pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Completed) IT (Completed) FR (Completed) NL (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024011-14 Sponsor Protocol Number: CBKM120D2201 Start Date*: 2011-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway
    Medical condition: Adult patients with metastatic NSCLC with activated PI3Kpathway.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005932-24 Sponsor Protocol Number: CBKM120F2202 Start Date*: 2012-07-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, phase II/III study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without ...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to weekly paclitaxel is effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) CZ (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005524-17 Sponsor Protocol Number: CBKM120F2302 Start Date*: 2012-09-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized, double-blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast ...
    Medical condition: This study will evaluate whether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with hormone receptor-positive HER2 negative locally advanced or metastatic b...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Completed) IT (Prematurely Ended) HU (Completed) FR (Completed) GR (Completed) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003602-25 Sponsor Protocol Number: CBEZ235B2203 Start Date*: 2011-12-13
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Estudio fase Ib/fase II aleatorizado, de BEZ235 y trastuzumab frente a lapatinib y capecitabina, en pacientes con cáncer de mama metastásico o localmente avanzado HER2 positivo, que no han respondi...
    Medical condition: Adult female patients with HER2 positive locally advanced or metastatic breast cancer who received prior trastuzumab treatment. Phase II: patients must have additionally received prior taxane thera...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024396-12 Sponsor Protocol Number: CBEZ235C2201 Start Date*: 2011-06-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma
    Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014745 Endometrial carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002400-32 Sponsor Protocol Number: CBEZ235B2101 Start Date*: 2011-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A dose-finding phase Ib study followed by an open-label, randomized phase II study of BEZ235 plus paclitaxel in patients with HER2 negative, inoperable locally advanced or metastatic breast cancer
    Medical condition: Adult female patients with HER2 negative breast cancer which is found to be inoperable locally advanced or metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-024394-39 Sponsor Protocol Number: CBEZ235B2201 Start Date*: 2011-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway
    Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) BE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000452-16 Sponsor Protocol Number: 156-03-244 Start Date*: 2004-08-02
    Sponsor Name:Otsuka Maryland Research Institute
    Full Title: International, Multi-Centre, Study of One year, Open Label, Titrated Oral Tolvaptan Tablet Administration in Patients with Chronic Hyponatraemia: Extension to Studies 156-02-235 and 156-03-238 to a...
    Medical condition: Ongoing hyponatraemia in euvolemic and hypervolemic states
    Disease: Version SOC Term Classification Code Term Level
    7 10021036 1.1
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002208-41 Sponsor Protocol Number: CBKM120Z2402 Start Date*: 2013-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000675-16 Sponsor Protocol Number: CBEZ235F2201 Start Date*: 2012-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuro...
    Medical condition: Adult patient in advanced pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) NL (Completed) DE (Completed) IT (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022015-19 Sponsor Protocol Number: CBKM120C2201 Start Date*: 2011-04-26
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: Estudio de fase II, de una sola rama, de BKM120 administrado por vía oral como tratamiento de segunda línea en pacientes con carcinoma endometrial avanzado
    Medical condition: Mujeres adultas con carcinoma endometrial avanzado cuya enfermedad ha progresado durante o después del tratamiento antineoplásico de primera línea para la enfermedad avanzada.
    Disease: Version SOC Term Classification Code Term Level
    13 10007063 Cáncer de endometrio LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001884-39 Sponsor Protocol Number: CBEZ235ZIC01 Start Date*: 2012-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa
    Medical condition: Adult patient with metastatic or unresectable malignant perivascular epithelioid cell tumors (PEComa)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024595-26 Sponsor Protocol Number: 287-11-201 Start Date*: 2011-10-27
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer
    Medical condition: Locally-advanced Pancreatic Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018796-21 Sponsor Protocol Number: 31-08-255 Start Date*: 2010-11-02
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018860-17 Sponsor Protocol Number: 31-08-257 Start Date*: 2011-04-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) EE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) FI (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018401-10 Sponsor Protocol Number: 156-08-271 Start Date*: 2010-07-07
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc
    Full Title: A Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 14:54:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA